Summary.-The results are reported of a small clinical trial carried out to assess the potential value of the hypoxic cell radiosensitizer misonidazole in the radiation treatment of Grade 3 and 4 supratentorial astrocytomas. A total of 55 patients were randomly allocated to one of 3 treatment groups. No significant differences were seen between the median survivals of patients in the 2 control radiation groups and that of the third group in which oral misonidazole at a dose of 3 g/m2 preceded each of 4 weekly radiation doses. Possible reasons why no improvement was seen are discussed in detail.
THE SURGICAL TREATMENT of Grade 3 and 4 supratentorial astrocytomas remains unsatisfactory, despite the many attempts to improve results by combinedmodality treatments with radiotherapy and chemotherapy. The median survival for patients treated by surgery alone is less than 6 months, and fewer than 500 survive at 3 years Bloom, 1975) . Postoperative radiotherapy marginally improves the results (Roth & Elvidge, 1960; Taveras et al., 1962; Hitchcock & Sato, 1964; Jelsma & Bucy, 1967; . The addition of chemotherapy with a nitrosourea to the postoperative radiotherapy improves survival further (BCNU Walker & Strike, 1979; Brisman et al., 1976; CCNU Hildebrand, 1979 ) though this is not confirmed in a smaller series with CCNU (Garrett et al., 1978) . The use of chemotherapy alone has remained disappointing (Hildebrand, 1979; .
The failure to control what is essentially a localized disease by radiotherapy is disappointing, and probably relates to the radiosensitivity of normal brain tissue, which does not permit curative radiation doses without unacceptable morbidity. Malignant gliomas are known to contain many necrotic areas, and it seems possible that resistance to radiation may be the result of hypoxic cells. Chemical radiosensitizers of hypoxic cells have been described in an experimental setting (Fowler et al., 1976) and in a small study of the radiation treatment of cerebral astrocytomas (Urtasun et al., 1976) (Bleehen, 1980) (Table II) . and 75, with a supraTreatment.-After stratification, patients iom histological con-were allocated on the basis of random numof Grade 3 or 4 astro-bers to one of the following treatment ned, were eligible for schedules: istory of other maligGroup A: 56-56 Gy (5656 rad) in 28 equal :ely to affect survival, fractions of 2-02 Gy/fraction over 51 wA-eeks ion, rendered patients (1702 ret).
-h gross neurological Group B: 43 52 Gy (4352 rad) in 12 unequal ;ciousness were also fractions over 4 weeks. These were delivered provided that it was thrice weekly with 2-94 Gy on Mondays and ier major defects, did Wednesdays and 5 Gy on Fridays.
Group C: The same radiation schedules as s were randomized to in Group B with the addition of MISO 3 g/m2 roups, after stratifica-given by mouth after a light breakfast 4-5 h irther criteria. These before the 5 Gy dose on Fridays. Thus a ents from whom most cumulative dose of 12 g/m2 of MISO w%as resected and for those given in 4 weekly doses. rate or small biopsy The radiation dose in Group A was selected on the basis of our previous experience. The schedules in Groups B and C were also calcu- significant deviation. ring system: Anticonvulsant therapy waAs given to a total of 26 of the 55 patients as follows: Group A-phenytoin 7; Group B-phenytoin partially confined to bed 4, phenobarbitone 3; Group C-phenytoin 9, phenobarbitone 2, both drugs 1. They were A confined to chair or bed maintained on these drugs at appropriate dosage from some time before radiotherapy was begun. No other anti-cancer drugs were given during the primary treatment. However, CCNU (13 patients) and procarbazine (1 patient) were used on relapse not less than 3 months after completion of the protocol therapy. The decision to give chemotherapy was made on the basis of the clinical condition of the patients, and without knowledge of the treatment they had previously received. Fewer patients received this second treatment in Group C (3 patients) than in Group A (6 patients) and Group B (5 patients). Plasma misonidazole estimation.-Full details of the method by reverse-phase highperformance chromotography have been reported elsewhere (Workman et al., 1978) . Plasma was prepared by centrifugation of heparinized blood at 4°C and samples stored at -20°C until analysed. Blood samples were always taken 4 h after drug ingestion, just before the radiation treatment. Additional samples were also taken at intervals before and after. 
RESULTS
Case accrual was stopped at the end of 1978 because new patients were then entered into a multicentre study coordinated by the Medical Research Council. All patients have been seen at regular intervals until death. No patient was lost to follow-up. The analysis presented in the Fig. and Table II represents a complete follow-up, as all patients have now died. It can be seen that no difference is apparent in the survival of patients treated by the three regimens. The median survivals for Group A are 251 days, for Group B, 220 days and for Group C, 270 days. The survival rate at 1 year of all groups of patients combined was 14/55 (25%).
There was some improvement in the performance status of patients after treatment, as seen in Table II, ceivably be quite small. In contrast, our Plasma MISO concentrations were study has shown no real improvement in monitored at the time of radiotherapy, survival as a result of treatment with i.e. about 4 h after each dose in 16/17 MISO. patients allocated to receive the drug. The
The poor result of the control group in mean plasma concentration was 92+ 32 the Canadian study may be ascribed to /g/ml, with an overall range of 49-189 jug/ the low radiation dose (1288 ret) as comml. There was some variation in the con-pared with those more conventionally centrations achieved after individual used. Thus in a series of protocols carried doses in the same patient. The maximum out by the N.C.I. Brain Tumour Study range in one patient over the 4 doses of the Group there was a drug was 49-94 ,ug/ml. The mean plasma progressive increase in median survival MISO half-life (t1) was 8*6 h + 0*62. with increasing radiation dose over the No patients developedsignificant periph-range 4500-6000 Gy (daily fractions for eral neuropathy. Assessment of central-5 days per week over 41-6 weeks). At the nervous-system toxicity was more diffi-highest dose, the median survival time cult, because of the nature of the disease was 42 weeks, similar to that seen in our being treated. We were not aware of any study but much longer than that in the such damage in our patients.
Canadian metronidazole group. Even longer median survival times have been DISCUSSION reported in a non-randomized study on patients; with Grade 3 tumours of 91 This study was based on the hypothesis weeks and of 42 weeks for Grade 4 that resistant hypoxic tumour cells con-tumours (Salazar et al., 1979) . It seems tribute to the poor results of the combined likely therefore that metronidazole imsurgical and radiotherapeutic manage-proved the poor results due to the low ment of high-grade cerebral astrocytomas. radiation dose in the study reported by The results are disappointing when com-Urtasun et al. Indeed, in a new study with pared with those presented by Urtasun more conventional radiation dosage, and his colleagues (1976) using metronid-metronidazole has not shown its previous azole. In that Canadian study, 31 assess-effectiveness (Urtasun, personal communiable patients were treated to a total cation, 1980). tumour dose of 30 Gy by 9 fractions (3 In our study there are several possible times per week) in an overall time of 18 reasons why no improvement in survival days, with radiation fields similar to that was seen after treatment with radiation used in our study. All received dexa-and MISO. methasone during and after radiotherapy, A relatively small number of patients were entered into the study for the reason already stated. With these numbers there was only a small chance of detecting an increase in median survival of 15 weeks (i.e. from 30 to 45 weeks) and no better than an even chance of detecting an increase of 25 weeks. Such a study could only be reasonably sure of detecting an increase in median survival time of 60 weeks minimum, so it is not particularly surprising that no difference was found.
A second possible reason is that radiobiological hypoxia may not be present in a significant amount in cerebral gliomas. Clinical studies using alternative techniques to overcome the potential problem of hypoxia in gliomas, such as hyperbaric 02 (Chang, 1977) and fast-neutron therapy Laramore et al., 1978; Batterman, 1980; Catterall et al., 1980) , have not demonstrated any improvement in survival over comparable patients treated by photons. There was, however, some reported improvement of local tumour control at postmortem examination. The data from the first metronidazole study (Urtasun et al., 1976 ) might also suggest that hypoxia was a problem, in that improvement due to the drug was noted, with the suboptimal radiation schedule.
A further reason for failure to demonstrate differences may relate to the treatment schedules which were adopted. There is no general agreement as to an optimum radiation dose and fractionation schedules for the treatment of gliomas. Conventionally, daily fractions of 1P8-2-0 Gy are given, to total doses of 45-65 Gy (Bloom, 1975; Salazar et al., 1979) . The tissue volume treated also varies from that of the whole brain with or without a boost to the tumour, to smaller more restricted volumes throughout the entire treatment. We opted to use as our control regimen, a schedule with which we had had much previous experience and which had produced a median survival of about 9 months. This was comparable to that achieved in most other reports, as discussed previously. At the time the study was designed, we believed that optimal radiosensitization by MISO would be obtained with the use of a few large drug doses in order to obtain high serum and therefore tumour concentrations. Because of its dose-limiting neurotoxicity (Dische et al., 1978) we restricted the total cumulative drug dose to 12 g/m2; and therefore elected that 4 treatment fractions be given of 3 g/m2 each. We also expected that it would be better to use large radiation fractions with these drug doses in order to achieve maximum tumour-cell kill. A preliminary pilot study demonstrated that 5Gy fractions were well tolerated. We therefore decided to give smaller radiation doses twice a week and reserve the larger dose with drug on Fridays to permit recovery of the patient from any excess cerebral oedema over the weekend. There were no adequate guidelines for a dose comparison between such a schedule and the conventional 5-dayweek regime, so it was therefore necessary to have an additional control of the unconventional regimen without sensitizers. The total doses were calculated to be equivalent in terms of NSD, as 1702 ret. (Orton & Ellis, 1973) . However, such calculations are probably only valid for skin and s.c. tissue from which the original NSD data were obtained. There is now evidence that the NSD formula (that is, with a fractional exponent of 0-24, and a time exponent of 0.11) may not apply in the calculation of centralnervous-system tolerance, at least for the rodent spinal cord (Van der Kogel, 1979; Hornsey & White, 1980) . Only a very large clinical study would detect minor differences, but it is reassuring that survival was not significantly different between the 2 control radiation groups.
Our initial premise that it would be best to administer the MISO in a few large fractions may also have been incorrect. It has subsequently been reported, on the basis of computer modelling, that multiple small doses of the sensitizer with conventional daily radiation fractions or sensitization at the beginning of a treatment course might be most advantageous (Denekamp et al., 1980) . However, the validity of this model still remains to be proved. An additional reason for the result might arise if MISO sensitized normal brain tissue to radiation. Although it is usually believed only to sensitize hypoxic cells and tissues (Fowler et al., 1976) , there remains the possibility that there is a degree of hypoxia in the central nervous system. Thus MISO sensitization has been reported in the spinal cord of the rat (Yuhas, 1979) , but anaesthesia may have contributed to this effect. Increased radiation reaction in the normal oropharyngeal mucosa of unaesthesized patients has also been documented (Arcangeli et al., 1980) . Once again hard data are still lacking on this topic.
We have been concerned as to the optimal time at which radiation treatment should be given after oral MISO. We selected 4-5 h on the basis of data from tumour biopsies at other sites (Gray et al., 1976; Wiltshire et al., 1978; Ash et al., 1979) . We have subsequently investigated this problem by estimating drug concentration in brain-tumour samples in a series of patients biopsied at different times after drug administration. Tumour concentrations comparable to those seen at other tumour sites are seen, with similar time course. This work will be reported in detail elsewhere. Unless the mean concentrations in tumour do not indicate adequate drug penetration to the smaller proportion of hypoxic cells, it seems unlikely that the drug concentration is inadequate to achieve radiosensitization.
Brief comment should be made on the absence of MISO-induced neurotoxicity from this study. We believe that this is the result of two separate phenomena. We have shown that anticonvulsant therapy with phenytoin (Workman et al., 1980) and phenobarbitone (unpublished) reduce the plasma half-life of MISO because of hepatic microsomal-enzyme induction. The t-of 8-6 h + 0-62 observed in this study, compared to 11*5 h + 3 8 in our experience of patients without brain tumours, suggests that increased drug metabolism may be reducing the peripheral-nerve exposure to MISO. This has been discussed in more detail elsewhere (Bleehen, 1980) . In addition, all our patients were receiving dexamethasone, and this drug has been reported to reduce the incidence of MISO neurotoxicity (Wasserman et al., 1980) .
In conclusion we can therefore only speculate as to the reasons for the outcome of the present study. The combined survival rate of 25% at 1 year and ultimate death of all patients leaves no room for complacency. There was also only a small improvement in the performance status of the patients so treated, though a few were able to return to a relatively normal life. Much work is still required to improve on these results, and the many on-going studies, including a large MRC trial, with a variety of fractionation schedules, may well resolve this issue.
